Eight Roads

Eight Roads is a global venture capital firm headquartered in Hamilton, Bermuda, and serves as the proprietary investment arm of Fidelity International Limited. Established in 1969, the firm manages approximately $11 billion in assets and has offices in the UK, China, India, Japan, and the US. Eight Roads focuses its investments primarily on the healthcare and technology sectors, leveraging a 50-year history of partnerships with over 500 companies. The firm aims to identify and support innovative businesses across various regions, including Asia, Europe, Israel, and the United States.

Alokik Advani

Managing Partner, Fidelity International Strategic Ventures

Umang Agarwal

Principal

Sanjay Aggarwal

Venture Partner

Hiroki Ashida

Vice President

Daniel Auerbach

Senior Managing Partner, Asia

Vytautas Balsys

Partner

Helena Barman

Investor

Virginia Bassano

Vice President

Shirish Belapure

Venture Partner

Daniel Benjamin

Associate

Bhushan Bopardikar

Vice President

Betty Cai

Partner

Arvind Chari

Vice President

Ted Chua

Partner

Lucile Cornet

Partner

Kevin Du

Senior Associate

Raj Dugar

Managing Partner, Asia

Martin Ericsson

Principal

Tamina Fogelberg

Associate

Siddhant Gandhi

Associate

Elaine Gao

Senior Associate

Antonin Gury-Coupier

Vice President

Davor Hebel

Managing Partner and Head of Europe

April Hu

Vice President

Tao Huang

Principal

Tammy Huang

Senior Associate

Tao Huang

Principal

Allen Huo

Vice President

Abhishek Jain

Vice President

Zang Jialun

Partner

Murata Junichi

Principal

Deepak Kanvinde

Venture Partner

Michiko Kohyama

Vice President

Shinichiro Komoto

Partner

Kavish Kothari

Principal

Chintan Kothari

Partner

Thomas Lin

Vice President

Rebecca Lin

Partner

Xin Liu

Partner

Allen Liu

Senior Associate

Maneesh Menon

Principal

Sophie Meralli

Vice President

Chersy Miao

Senior Associate

David Milstein

Managing Partner and Head of Japan

Jens Neisius

Vice President

Dan O'Toole

Vice President

Yosuke Ouchi

Principal

Delphine Qiu

Principal

Eyal Rabinovich

Principal

Laura Salesse

Senior Associate

Fuga Sawada

Senior Associate

Shawn Shen

Partner

Sagar Sheth

Vice President

Lei Shi Ph.D

Partner

Arjun Singh

Senior Associate

Michael Stephanblome

Venture Partner

Liena Suzuki MD

Principal

Aditya Gurunath Systla

Principal

Michael Treskow

Partner

Jarlon Tsang

Managing Partner and Head of China

Ashish Venkataramani

Partner

Ashish Venkataramani

Partner

He Wang

Vice President

Bo Wang

Senior Associate

Nancy Xu

Vice President

Cody Yin Ph.D

Partner

Zhang Yixiao

Executive Director

Yuan Yuan

Principal

Alston Zecha

FinTech and Enterprise Software and Director

Haoming Zhang

Vice President

Gordon Zhang

Vice President and Principal

Feng Zhao

Partner

Weimin Liu Ph.D

Partner

Past deals in New Jersey

Doceree

Series B in 2023
Doceree Inc is a healthcare marketing technology company that operates a programmatic physician engagement and advertising platform. Founded in 2019 and based in Parsippany, New Jersey, with an additional office in New Delhi, India, Doceree specializes in connecting pharmaceutical and healthcare brands with healthcare professionals (HCPs). The platform enables targeted advertising and provides data analytics to help clients effectively reach and engage with HCPs in a compliant manner. Utilizing artificial intelligence and data segmentation, Doceree identifies specific HCPs across various digital platforms, including physician networking sites, medical journals, and telemedicine platforms. This approach allows healthcare industry professionals to deliver precise and transparent messaging at scale, catering to the needs of media agencies, pharmaceutical brands, medical device companies, consumer healthcare brands, and hospitals.

Doceree

Series A in 2022
Doceree Inc is a healthcare marketing technology company that operates a programmatic physician engagement and advertising platform. Founded in 2019 and based in Parsippany, New Jersey, with an additional office in New Delhi, India, Doceree specializes in connecting pharmaceutical and healthcare brands with healthcare professionals (HCPs). The platform enables targeted advertising and provides data analytics to help clients effectively reach and engage with HCPs in a compliant manner. Utilizing artificial intelligence and data segmentation, Doceree identifies specific HCPs across various digital platforms, including physician networking sites, medical journals, and telemedicine platforms. This approach allows healthcare industry professionals to deliver precise and transparent messaging at scale, catering to the needs of media agencies, pharmaceutical brands, medical device companies, consumer healthcare brands, and hospitals.

B-One

Series B in 2021
B-One Ortho Corp. is a manufacturer of orthopedic healthcare solutions, specializing in artificial joints that facilitate joint replacement surgeries. Founded in 2015 and headquartered in Cedar Knolls, New Jersey, the company also maintains offices in Shanghai and Suzhou, China. Its notable products include the B-One total hip system, which features advanced coating technology and instrumentation, as well as the Juveno bone-conserving femoral prosthesis and primary acetabular systems. These innovations aim to enhance the effectiveness of hip and knee arthroplasty, ultimately helping patients regain their mobility and improve their quality of life.

B-One

Venture Round in 2020
B-One Ortho Corp. is a manufacturer of orthopedic healthcare solutions, specializing in artificial joints that facilitate joint replacement surgeries. Founded in 2015 and headquartered in Cedar Knolls, New Jersey, the company also maintains offices in Shanghai and Suzhou, China. Its notable products include the B-One total hip system, which features advanced coating technology and instrumentation, as well as the Juveno bone-conserving femoral prosthesis and primary acetabular systems. These innovations aim to enhance the effectiveness of hip and knee arthroplasty, ultimately helping patients regain their mobility and improve their quality of life.

B-One

Series A in 2018
B-One Ortho Corp. is a manufacturer of orthopedic healthcare solutions, specializing in artificial joints that facilitate joint replacement surgeries. Founded in 2015 and headquartered in Cedar Knolls, New Jersey, the company also maintains offices in Shanghai and Suzhou, China. Its notable products include the B-One total hip system, which features advanced coating technology and instrumentation, as well as the Juveno bone-conserving femoral prosthesis and primary acetabular systems. These innovations aim to enhance the effectiveness of hip and knee arthroplasty, ultimately helping patients regain their mobility and improve their quality of life.

Symbiomix Therapeutics

Venture Round in 2018
Symbiomix Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for women's health infections, particularly bacterial vaginosis (BV). Founded in 2012 and headquartered in Newark, New Jersey, with additional offices in Baltimore, Maryland, and Hamden, Connecticut, the company specializes in the development of its lead product, Solosec (secnidazole), a next-generation 5-nitroimidazole antibiotic designed for a convenient one-dose treatment. This drug offers enhanced pharmacokinetic properties that improve efficacy and tolerability for patients. Symbiomix is supported by prominent healthcare venture capital firms and aims to address the unmet therapeutic needs in the field of gynecologic infections. Since October 2017, it has operated as a subsidiary of Lupin Inc.

B-One

Venture Round in 2018
B-One Ortho Corp. is a manufacturer of orthopedic healthcare solutions, specializing in artificial joints that facilitate joint replacement surgeries. Founded in 2015 and headquartered in Cedar Knolls, New Jersey, the company also maintains offices in Shanghai and Suzhou, China. Its notable products include the B-One total hip system, which features advanced coating technology and instrumentation, as well as the Juveno bone-conserving femoral prosthesis and primary acetabular systems. These innovations aim to enhance the effectiveness of hip and knee arthroplasty, ultimately helping patients regain their mobility and improve their quality of life.

Transave

Venture Round in 2006
Transave, Inc., a biotechnology company, develops inhaled pharmaceuticals for the treatment of lung diseases. The company’s liposomal technology allows the release of drug in the lung's microenvironment. Its products also include Arikace for the treatment of gram-negative lung infections and pseudomonas infections in cystic fibrosis patients; and cisplatin lipid complex for the treatment of cancers affecting the lungs. Transave, Inc. was founded in 1997 and is headquartered in Monmouth Junction, New Jersey. As of December 1, 2010, Transave, Inc. operates as a subsidiary of Insmed Incorporated.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.